Deep Sequencing of FLT3 ‐ITD Enables Response Evaluation and Post‐Treatment Monitoring in Childhood AML: An Exploratory Study
Pediatric Blood & Cancer · 2026-08 · 73 (8)
DOI: 10.1002/1545-5017.70397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 18.05.2026. Verfasst von Sofie Johansson Alm und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, High-Throughput Nucleotide Sequencing, Neoplasm, Residual. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish state under the agreement between the Swedish government and the county councils; the ALF-agreement, Barncancerfonden, Sahlgrenska University Hospital Research Foundations.
Abstract (Originalsprache)
Background
An internal tandem duplication in the gene encoding Fms‐like tyrosine kinase 3 ( FLT3 ‐ITD) is associated with high relapse risk and poor prognosis in acute myeloid leukemia (AML) and plays a crucial role in treatment decisions. Measurable residual disease (MRD) analysis of FLT3 ‐ITD during and after treatment has shown prognostic value in adults, but its clinical value in children remains unexplored. Procedure This study evaluated the potential of MRD analysis with deep sequencing (ultrahigh‐sensitivity next‐generation sequencing; UHS‐NGS) of FLT3 ‐ITD to assess treatment response and predict impending relapse in children with AML. A total of 168 samples from 17 patients (median age 11 years, range: 4–17) were analyzed. Bone marrow samples were used for evaluation of treatment response, and peripheral blood samples for post‐treatment monitoring.
Results
Deep sequencing enabled monitoring of the kinetics of FLT3 ‐ITD subclones throughout treatment. When used for post‐treatment monitoring, deep sequencing detected increasing levels of FLT3 ‐ITD in peripheral blood only in patients who relapsed, while no such increase was detected in patients in continuous complete remission. Comparisons with flow cytometry and deep sequencing of other mutations confirmed the sensitivity of the assay and the often subclonal nature of FLT3 ‐ITD.
Conclusions
Deep sequencing of FLT3 ‐ITD is a highly sensitive method for MRD monitoring in children with AML, with significant potential for assessing treatment response and detecting imminent relapse at an early stage. It may serve as a valuable molecular MRD method, especially as a complement to flow cytometry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
- Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden.
- Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden.
- Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany.
- Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden.
ORCID-Profile: Sofie Johansson Alm, Kristian Løvvik Juul-Dam, Borhan R Saeed, Anna Staffas
Förderung
- Swedish state under the agreement between the Swedish government and the county councils; the ALF-agreement
- Barncancerfonden
- Sahlgrenska University Hospital Research Foundations
- Stiftelsen Assar Gabrielssons Fond
Zitieren
APA
Alm, S. J., Tornberg, B., Malmberg, E. D., Hasle, H., Juul-Dam, K. L., Palmqvist, L., Saeed, B. R., Barkhordar, G. S., Soboli, A., Staffas, A., Abrahamsson, J., & Fogelstrand, L. (2026). Deep Sequencing of FLT3 ‐ITD Enables Response Evaluation and Post‐Treatment Monitoring in Childhood AML: An Exploratory Study. Pediatric Blood & Cancer, 73(8). https://doi.org/10.1002/1545-5017.70397
Vancouver
Alm SJ, Tornberg B, Malmberg ED, Hasle H, Juul-Dam KL, Palmqvist L, et al. Deep Sequencing of FLT3 ‐ITD Enables Response Evaluation and Post‐Treatment Monitoring in Childhood AML: An Exploratory Study. Pediatric Blood & Cancer. 2026;73(8). doi:10.1002/1545-5017.70397
BibTeX
@article{Alm2026,
author = {Alm, Sofie Johansson and Tornberg, Bea and Malmberg, Erik Delsing and Hasle, Henrik and Juul-Dam, Kristian Løvvik and Palmqvist, Lars and Saeed, Borhan R and Barkhordar, Giti Shah and Soboli, Anastasia and Staffas, Anna and Abrahamsson, Jonas and Fogelstrand, Linda},
title = {Deep Sequencing of FLT3 ‐ITD Enables Response Evaluation and Post‐Treatment Monitoring in Childhood AML: An Exploratory Study},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {8},
doi = {10.1002/1545-5017.70397}
}
EUVIMED